• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer wherein from about 4% to about 12% by weight of the polymer is a chlorine anion and a pharmaceutically acceptable carrier or diluent.
    公开号:KR20040018357A
    申请号:KR10-2003-7013677
    申请日:2002-04-10
    公开日:2004-03-03
    发明作者:존 에스. 피터센；스티븐 케이쓰 부르케；스티븐 랜달 홈즈-팔리
    申请人:젠자임 코포레이션；
    IPC主号:
    专利说明:

    Low salt polyallylamine {LOW SALT FORMS OF POLYALLYLAMINE}
    [1] Polyallylamine polymers have found many uses as therapeutic agents in recent years. For example, polyallylamine has been reported to be effective in treating patients with elevated serum phosphate levels and hyperphosphatemia (eg, US Pat. Nos. 5,496,545 and 5,667,775). Serum phosphate elevations are often seen in patients with overdose of therapeutic agents, including renal failure, hypothyroidism, acute untreated acromegaly, and phosphates. Polyallylamine is also used as a bile acid sequestrant (eg, US Pat. Nos. 5,624,963, 5,703,188, 5,840,766, and 6,060,517) and was used to lower uric acid levels (US Pat. No. 5,985,938). Of particular interest is Sevelamer, a drug approved by the US Food and Drug Administration for the treatment of hyperphosphatemia.
    [2] A unique structural feature of the polyallylamine polymer is that there are repeat units from the polymerized allylamine monomer. For example, seversamers are homopolymers comprising repeating units that are unsubstituted with amine nitrogen from polymerized allylamine monomers. The structure of the repeating unit from the seversamer homopolymer is shown by the following structural formula (I):
    [3]
    [4] For other polyallylamines, the amine nitrogen in the polymerized allyl monomer repeat unit is substituted. Suitable substituents are described below.
    [5] In order to maintain efficacy and prevent undesirable side effects, it is very important that the components in the pharmaceutical product, including the pharmacologically active component, typically be chemically stable over a long period of time of two years or more. During this period, the rate of degradation should be within acceptable limits. However, amine compounds are sensitive to oxidative degradation. For this reason, drugs containing amine functionality are generally stored and administered in the form of salts, typically hydrochloride (HCl) salts, which salt forms are more stable than the corresponding free amines in most cases. For example, Seversamer is stored and administered as a salt in which about 40% of the amine groups are protonated as hydrochloride salts (about 18% by weight of the polymer is chloride).
    [6] Summary of the Invention
    [7] Surprisingly, a proportion significantly lower than 40% of the amine groups was found to degrade the protonated amine-containing polymer at a rate within acceptable limits in terms of drug stability. There are established guidelines for drug stability testing in the art, including the following guidelines: International Conference on Harmonization (ICH), Section Q1A "Stability Testing of New Drug Substances and Products" (Revised); And the Code of Federal Regulations (CFR), 21 CFR 211.166 "Guideline for Submitting Documentation for the Stability of Human Drugs and Biologicals". For example, under accelerated stability test conditions, polyallylamine hydrochloride with about 4.0 wt% to about 12 wt% chloride was found to exhibit minimal degradation and can be stored for at least two years. In addition, these polyallylamine hydrochlorides in "low chloride" or "low salt" form have the same desirable therapeutic and formulation properties as the corresponding polymers with high levels of chloride. Based on this finding, stable pharmaceutical formulations of polyallylamine polymers with low levels of protonation and novel pharmaceutical compositions comprising the polymers are described herein. As used herein, the term “stable” as used in connection with a polymer and its pharmaceutical formulation means that the pharmaceutical formulation of the polymer degrades at a rate within acceptable limits in terms of drug stability but retains therapeutic effectiveness.
    [8] One embodiment of the invention is a stable polyallylamine polymer wherein from about 9.0% to about 27.0% of the amine groups in the polyallylamine are protonated (eg, from about 4.0% to about 12.0% by weight of the polymer is chlorine). Polyallylamine hydrochloride as an anion). More preferably, about 11% to about 20.0% of the amine groups in the polyallylamine polymer are protonated (e.g., polyallylamine hydrochloride in which about 5.0% to about 9.0% by weight of the polymer is a chlorine anion) . The amine group is preferably protonated as a hydrochloride salt.
    [9] Another embodiment of the present invention is a pharmaceutical composition comprising the stable polyallylamine polymer described above and a pharmaceutically acceptable carrier or diluent.
    [10] The polyallylamine in low salt form has significant therapeutic and drug formulation advantages compared to corresponding polymers with higher salt levels. For example, polyallylamine is commonly used to reduce phosphate serum levels in patients with kidney failure. Unfortunately, most patients with kidney failure suffer from low blood pH or “acidosis”. Polyallylamine in the low salt form tends to elevate blood pH, as it releases less anions into the blood and has a higher number of unprotonated basic amines compared to higher salt form polymers. Second, the low salt content makes formulation and administration easier by reducing the weight and volume of the ultimate formulation.
    [11] Polyallylamine is a polymer with repeat units from polymerized allyl amine monomer (s). The amine group of the allyl monomer is unsubstituted or substituted, for example, with one or two C 1 -C 10 linear or branched alkyl groups. The alkyl group (s) may or may not be substituted with one or more hydroxyl, amine, halo, phenyl, amide or nitrile groups. Preferably, the polyallylamine polymer of the present invention comprises a repeating unit represented by the following structural formula (I):
    [12]
    [13] Polyallylamine is a copolymer comprising repeat units from at least two different polymerized allyl monomers or repeat units from polymerized allyl monomer (s) and repeat units from monomer (s) other than polymerized allyl. Copolymer with Examples of suitable non-allyl monomers are acrylamide monomers, acrylate monomers, maleic acid, maleimide monomers, vinyl acylate monomers and alkyl substituted olefins. Preferably, however, the polyallylamine of the present invention comprises only repeating units from polymerized allyl amine monomers. More preferably, the polyallylamine polymer of the present invention is a homopolymer. Even more preferably, the polyallylamine polymer of the present invention is a homopolymer of repeating units represented by formula (I).
    [14] Although polyallylamine may not be crosslinked, crosslinking is preferred. Suitable crosslinkers include epichlorohydrin, 1,4 butanediol diglycidyl ether, 1,2 ethanediol diglycidyl ether, 1,3-dichloropropane, 1,2-dichloroethane, 1,3-dibro Morphopane, 1,2-dibromoethane, succinyl dichloride, dimethylsuccinate, toluene diisocyanate, acryloyl chloride, and pyromellitic dianhydride. Epichlorohydrin is a preferred crosslinking agent. Typically about 9% to about 30%, preferably 15% to about 21% of allyl nitrogen atoms are bonded to the bridging group. Preferably, epichlorohydrin is a crosslinking agent, which produces a 2-hydroxypropyl crosslinking group.
    [15] Polyallylamines can be protonated by organic or inorganic acids containing physiologically acceptable anions. The anions may be partially or wholly substituted with other physiologically acceptable anions by various means including passing the polymer on the anion exchange resin prior to crosslinking. Examples of suitable inorganic anions are halides (particularly chlorides), carbonates, bicarbonates, sulfates, disulfates, hydroxides, nitrates, persulfates and sulfites. Suitable organic acids include acetates, ascorbates, benzoates, citrates, dihydrogen citrate, hydrogen citrate, oxalates, succinates, tartarates, taurocholates, glycocholates and cholates. Chloride is the preferred anion.
    [16] In one preferred embodiment, the polyallylamine polymer is crosslinked by epichlorohydrin and about 9% to about 30% (preferably about 15% to about 21%) of allyl nitrogen atoms are bonded to the crosslinking group , Anion is chloride. More preferably, the polyallylamine polymer is a homopolymer. Even more preferably, the polyallylamine polymer is a homopolymer comprising repeating units represented by formula (I).
    [17] In a preferred embodiment, the polyallylamine polymer is a homopolyallylamine crosslinked with about 9.0 to 9.8%, preferably 9.3 to 9.5% of epichlorohydrin, which is the activity of a drug known as Severamer HCl. Chemical composition.
    [18] The polyallylamine polymer described herein treats a number of diseases including hyperphosphatemia (eg, patients with high serum phosphate levels, such as patients with end-stage nephropathy, hypothyroidism, acromegaly, and phosphate overdose). Useful for The polymers described herein are also suitable as bile acid sequestrants for the prevention of thrombosis of anastomosis, such as in the treatment of Wilson's disease, for lowering uric acid levels in patients, and for use in connection with kidney dialysis. A dose of about 0.5 g / day to about 10 g / day is typical, preferably about 3 g / day to about 6 g / day.
    [19] The polymer may be administered alone or in a pharmaceutical composition comprising the polymer, a pharmaceutically acceptable carrier or diluent, and optionally one or more additional drugs. The polymer is preferably administered orally, more preferably orally with a meal. Preferred carriers and diluents will be readily apparent to those skilled in the art. Such carrier and diluent materials which are inorganic or organic include, for example, silicon oxide, stearic acid, gelatin, albumin, lactose, starch, magnesium stearate, preservatives (stabilizers), melts, emulsifiers, salts and buffers. The therapeutically effective amount can be administered in a series of doses at appropriate time intervals such as minutes or hours.
    [20] Further descriptions of suitable dosages, formulations, and routes of administration are provided in US Pat. Nos. 5,496,545, 5,667,775, 6,083,495, 5,702,696, and 5,487,999. These patents are hereby incorporated by reference in their entirety.
    [21] The invention is illustrated by the following examples which are not intended to be limiting in any way.
    [22] Example 1 Preparation of Low Chloride Severamer Hydrochloride (Polyallylamine Homopolymer)
    [23] Various chloride levels (about 1 wt.%, About 5 wt.%, About 9 wt.%) Of Seversamer HCl are commercially available bulk seversamers (about 18 wt.%) Manufactured by Dow Chemicals, Midland, Michigan. Chloride). The bulk seversamer was slurried in water and further neutralized with 50% aqueous sodium hydroxide (NaOH) solution. Various amounts of NaOH were added to reduce the chloride to the desired weight level based on the polymer. For example, 0.5 equivalents of NaOH added based on total chloride (about 18%) in Renagel reduced chloride by about 50%, resulting in a seversamer with about 9% by weight of the polymer chloride, 0.75 equivalents of NaOH Reduced the chloride by about 75% to produce a seversamer with about 5 wt% chloride, and at least 0.95 equivalents of NaOH produced a seversamer with about 1 wt% chloride.
    [24] The neutralized seversamer was filtered and resuspended in an appropriate amount of water so that the conductive slurry was less than 1 mS / cm. The suspension was filtered and placed in a 70 ° C. forced air oven until dry. Thereafter, the dried Seaveramer was crushed and sieved.
    [25] Alternatively, polyallylamine polymers crosslinked with epichlorohydrin are synthesized as described in US Pat. Nos. 5,496,545, 5,667,775, 6,083,495, 5,702,696 and 5,487,999 and neutralized as described above. Thus, the desired weight percent chloride can be obtained based on the polymer.
    [26] Example 2 Stability Test with Low Chloride Seversamer HCl
    [27] The low chloride seversamer hydrochloride polymers (polyallylamine homopolymers) described in Example 1, each having about 9%, 5%, and 1% chloride by weight of the polymer, were used in International Conference on Harmonization (ICH) The stability was tested according to the instructions of The accelerated stability test included placing each low chloride polymer sample in a 40 ° C. oven with 75% relative humidity for 1 month, 2 months, 3 months and 6 months. At each time point, a portion of each polymer sample was separated and analyzed using two assays, a phosphate binding assay and a soluble oligomer assay. Both assays have been demonstrated as stability indication assays for polyallylamine polymers.
    [28] The phosphate binding assay measures the phosphate binding capacity of Severamer hydrochloride, which is an indicator of therapeutic effectiveness. This assay was performed by mixing the Severamer hydrochloride sample with a solution of known phosphate concentration, filtering the polymer-phosphate complex, and quantifying the unbound phosphate concentration by ion chromatography.
    [29] Soluble oligomer assay measures the amount of soluble oligomer in each seversamer hydrochloride sample. Tittable amine and soluble oligomer content indicate polymer stability at each time point. This assay was performed by reacting ninhydrin with oligomers extracted from a sample of Severamer hydrochloride at each time point. Spectrophotometric quantitation to determine the amount of residual soluble oligomers was performed by comparing the absorbance of the derivatized sample extract with that of known standards.
    [30] The results of the stability test show that the samples with 9 wt% and 5 wt% chloride composition have a very good stability profile (the sample retains the ability to bind phosphate, and the residual soluble oligomer level is applied to each sample). Means within acceptable limits). The results of this experiment showed that low chloride variants of Severamer hydrochloride with 9 and 5 wt% chloride composition, respectively, had Severamer hydrochloride with about 18% chloride content (chloride content found in commercially available Severamer drugs). It has a similar stability profile. Accelerated stability results further indicate that the shelf life of low chloride Seversamer hydrochloride drugs is equivalent to more than two years.
    [31] While the invention has been shown and described in detail with reference to its preferred embodiments, those skilled in the art will understand that various changes in form and detail may be made therein without departing from the scope of the invention, which is protected by the appended claims. .
    权利要求:
    Claims (7)
    [1" claim-type="Currently amended] A pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer wherein from about 4% to about 12% by weight of the polymer is a chlorine anion and a pharmaceutically acceptable carrier or diluent.
    [2" claim-type="Currently amended] The pharmaceutical composition of claim 1, wherein about 5% to about 9% by weight of the polymer is a chlorine anion.
    [3" claim-type="Currently amended] 3. A pharmaceutical composition according to claim 2 wherein the polymer is a homopolymer.
    [4" claim-type="Currently amended] 4. A pharmaceutical composition according to claim 3 wherein the polymer comprises repeating units represented by the following structural formula (I):

    [5" claim-type="Currently amended] The pharmaceutical composition of claim 4, wherein the polymer is crosslinked.
    [6" claim-type="Currently amended] 6. A pharmaceutical composition according to claim 5 wherein the polymer is crosslinked by a 2-hydroxypropyl crosslinking group.
    [7" claim-type="Currently amended] A pharmaceutical composition comprising a stable polyallylamine homopolymer comprising a repeating unit represented by the following structural formula (I) and a pharmaceutically acceptable carrier or diluent, wherein the homopolymer is crosslinked by a 2-hydroxypropyl group and homologous A pharmaceutical composition wherein from about 9% to about 30% of the amine groups in the polymer are bonded to one of the 2-hydroxypropyl crosslinking groups, and from about 5% to about 9% by weight of the homopolymer is a chlorine anion:
    类似技术:
    公开号 | 公开日 | 专利标题
    JP5903111B2|2016-04-13|Direct compression polymer tablet core
    Bergqvist et al.1992|Low molecular weight heparin for thromboprophylaxis and epidural/spinal anaesthesia–is there a risk?
    US6433026B2|2002-08-13|Process for removing bile salts from a patient and alkylated compositions therefor
    AU2004311849B2|2009-04-02|Enteric coated aliphatic amine polymer bile acid sequestrants
    US5236701A|1993-08-17|Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
    JP5758945B2|2015-08-05|Aliphatic amine polymer salt for tablet manufacture
    US5496545A|1996-03-05|Phosphate-binding polymers for oral administration
    ES2318823T3|2009-05-01|Poimeros burning anions and applications of the same.
    US6290946B1|2001-09-18|Anionic polymers as toxin binders and antibacterial agents
    KR101199608B1|2012-11-08|Methods and compositions for treatment of ion imbalances
    DE69923074T2|2005-12-08|Orange rasch release medicine to be used contains peptide thrombin antibody and a mixture of microcyristalline cellulose and sodium strength glycollates
    US6955806B2|2005-10-18|Ionene polymers and their use as antimicrobial agents
    US5500212A|1996-03-19|Crosslinked anion exchange particles and method for producing the particles
    US20150056278A1|2015-02-26|Direct Compression Polymer Tablet Core
    ES2637020T3|2017-10-10|Use of amine polymer to reduce serum glucose
    AU2001289699B2|2006-06-01|New pharmaceutical composition
    JP4649039B2|2011-03-09|Method for treating hypercholesterolemia using unsubstituted polydiallylamine
    KR100224539B1|1999-10-15|Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
    US20190240252A1|2019-08-08|Pharmaceutical compositions
    AU729205B2|2001-01-25|Cationic polymers as toxin-binding agents
    US6083495A|2000-07-04|Method of making phosphate-binding polymers for oral administration
    KR100556324B1|2006-03-03|A pharmaceutical composition comprising a lipase inhibitor and a bile acid sequestrant
    CA2349620C|2008-04-08|Use of aliphatic polyamines for reducing oxalate
    US5919832A|1999-07-06|Amine polymer sequestrant and method of cholesterol depletion
    AU2002346034B2|2005-10-13|Fat-binding polymers
    同族专利:
    公开号 | 公开日
    US20020159968A1|2002-10-31|
    ZA200308065B|2004-09-14|
    JP5243466B2|2013-07-24|
    BR0209020A|2004-08-10|
    AT331525T|2006-07-15|
    CA2444587A1|2002-10-31|
    EP1379258A1|2004-01-14|
    NZ528829A|2006-06-30|
    MXPA03009572A|2004-02-12|
    HK1058620A1|2006-08-18|
    WO2002085378A1|2002-10-31|
    JP2010111704A|2010-05-20|
    US20100068167A1|2010-03-18|
    EP1379258B1|2006-06-28|
    DE60212819D1|2006-08-10|
    CA2444587C|2008-10-21|
    DE60212819T2|2006-11-23|
    US7541024B2|2009-06-02|
    ZA200308063B|2005-01-17|
    ES2268013T3|2007-03-16|
    US8377428B2|2013-02-19|
    JP2004526777A|2004-09-02|
    JP5170932B2|2013-03-27|
    CN1503676A|2004-06-09|
    AU2002252632B2|2004-09-23|
    CN1290515C|2006-12-20|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2001-04-18|Priority to US28444501P
    2001-04-18|Priority to US60/284,445
    2002-04-10|Application filed by 젠자임 코포레이션
    2002-04-10|Priority to PCT/US2002/011408
    2004-03-03|Publication of KR20040018357A
    优先权:
    申请号 | 申请日 | 专利标题
    US28444501P| true| 2001-04-18|2001-04-18|
    US60/284,445|2001-04-18|
    PCT/US2002/011408|WO2002085378A1|2001-04-18|2002-04-10|Low salt forms of polyallylamine|
    [返回顶部]